|By PR Newswire||
|March 17, 2014 01:08 PM EDT||
NEW YORK, March 17, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The 3D printing industry has come a long way over the last many years; the technology has the potential of revolutionising the way things occur currently. Many industries have already benefitted from multiple advancements in this field, resulting in improved and more efficient processes worldwide. A quick look at www.3dprintingchannel.com suggests that 3D printing has multi-faceted dimensions; the technology has recently been used in varied industries such as automotive, medical, business, industrial equipments, education, architecture, and consumer products. There is a widespread optimism that it is likely to gain prominence in the coming years and have a far reaching impact on our daily lives.
Within healthcare, 3D printed prosthetics and implants have already been in the market for some years. Layerwise from Belgium and Xilloc from Netherlands are the major companies dealing with 3D printed medical and dental implants. Xilloc was in the news recently for creating the first customized 3D-printed lower jaw for an 83-year old patient with a serious jaw infection. Another company, Oxford Performance Materials, from USA, received FDA approval for a 3D printed implant that replaced 75% of a man's skull.
Specifically, 3D bioprinting is gradually emerging as an area which is garnering attention from a lot of academicians. Some of these researchers have also recently opened start-up firms with the aim of commercialising the technology over the next decade or so.
SCOPE OF THE REPORT
The '3D Bioprinting, 2014 - 2030' report provides an extensive study of the emerging market of 3D bioprinting, specifically focusing on commercial bioprinters and those under development, their applications and the likely future evolution. It is widely anticipated that the 3D bioprinting market has tremendous potential: it requires hardware (bioprinters), software (CAD), biocompatible materials (bio-ink and bio-paper), each of which has the capability to grow into separate niche industries. The report covers various aspects such as technological progress, product pipeline, industry and academic research programs and regulatory concerns to assess new evolving opportunities.
One of the key objectives of this report is to understand the current and future state of the bioprinters and products derived thereof. This is done by analysing the following:
- Commercial 3D Bioprinters currently available in the market
- Innovations of academic groups across various research institutes across the globe
- Competing technologies with similar applications in the healthcare industry
- Size of target consumer segments
- The widening supply-demand gap, specifically for organ transplants.
The base year for the report is 2014. The report provides short-mid term and long term market forecasts for the period 2014 - 2024 and 2024 - 2030, respectively. We have discussed, in detail, key drivers behind the likely growth of 3D bioprinting market. The research, analysis and insights presented in this report include the sales potential of various 3D bioprinted products based on the current expected market launch timelines, their adoption rates and the estimated end-use price points. The figures mentioned in this report are in USD, unless otherwise specified.
1. As of today, the industry is primarily focused on research and development; apart from the limited number of industry initiatives, academic groups worldwide are involved in exemplary research in the field of 3D bioprinting.
2. A number of start-ups have recently sprung up to develop products based on bioprinting; some of these are spin outs from university research. Examples include TeViDo BioDevices (focused on printing breast tissue), Aspect Biosystems (focused on printing tissue models for toxicity testing) and SkinPrint (focused on developing human skin).
3. The market currently has 14 industry sponsored bioprinters, focused on a variety of commercial applications. The widening supply-demand gap for organ transplants is a huge unmet need; the eventual goal of researchers is to be able to produce bioprinted organs for organ transplants.
4. As the development progresses, the next generation of bioprinters are likely to offer additional features (e.g. multiple arms) and are likely to be relatively more affordable driving wider adoption.
5. We believe that the market will progress gradually over the coming decade; however, the focus is likely to shift from research to commercialisation by the second half of next decade. At this stage, applications such as drug testing and tissue engineering (skin and cartilage) are likely to be popular.
6. By 2030, we predict 3D bioprinting to be a multi-billion dollar industry; early success of bioprinted organ transplants is likely to provide additional boost in subsequent years.
Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
1. Annual reports
2. Investor presentations
3. SEC filings
4. Industry databases
5. News releases from company websites
6. Government policy documents
7. Other analysts' opinion reports
While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on where the 3D bioprinting market is headed in the mid-long term.
Chapter 3 provides a general introduction to 3D bioprinting. We have discussed, in detail, the origins of 3D printing and recent developments which have shaped the industry so far. The chapter also elaborates on the 'bioprinting' process, current and future applications, and the challenges which have to be overcome before wider adoption of the technology.
Chapter 4 provides an overview of the 3D bioprinting market with respect to the available bioprinting technologies and companies active in the field. The analysis also extends to regional evolution and the key drivers which will determine the future growth.
Chapter 5 offers a comprehensive review of the major bioprinters which have been made available by leading companies in the market. We present profiles of eight technologies with information about their origin, printing process, applications, principal features, current status and expected future evolution.
Chapter 6 reviews, in detail, the major bioprinters offered by academic institutions dominant in the field. We present profiles of five leading technologies with information about their origin, printing process, applications, principal features, current status and likely future evolution.
Chapter 7 analyses the current and future state of the worldwide market of 3D bioprinting. The chapter includes our estimates of the value of the market for end-user applications till 2030. Given the current niche nature of the technology, we have done a multi-variate sensitivity analysis to present three different tracks of industry's evolution.
Chapter 8 provides our analysis of the strengths, weaknesses, opportunities and threats in the 3D bioprinting market, capturing the key elements likely to influence future growth.
Chapter 9 provides case studies on Organovo and regenHU, two companies active in the 3D bioprinting arena. The case studies include detailed analysis of financial performance (where available), marketed / pipeline bioprinting products, recent developments, and future focus areas.
Chapter 10 is a collection of six transcripts based on our discussion with some of the leading players in the industry. The companies / academic institutes interviewed include n3D Biosciences, regenHU, Sciperio / nScrypt, MicroFab Technologies, Digilab and TeVido BioDevices.
Chapter 11 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.
Chapters 12 and 13 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3.1. Chapter Overview
3.2. 3D Printing Technology
3.2.1. What is 3D Printing?
3.2.2. Historical Evolution
3.3. 3D Bioprinting Process And Components
3.4. Entry of 3D Printing into Medical Arena
3.4.1. Key Players
3.4.2. 3D Bioprinting Applications
184.108.40.206. Toxicity Screening / Drug Testing
220.127.116.11. Tissue Engineering
18.104.22.168. Organ Replacement via Organ Printing
22.214.171.124. High Initial Cost
126.96.36.199. Regulatory Issues
188.8.131.52. Functional Aspects Not Yet Fully Tested
184.108.40.206. Limited Capability for Complicated Tissues and Organs
220.127.116.11. Hurts Moral and Religious Beliefs
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Limited Professional Bioprinters in Market
4.3. Prices are Largely Prohibitive
4.4. The US is Leading the Efforts; Developing Countries Have Begun to Contribute
4.5. Start-ups Emerging as Key Players
4.6. Bioprinting: Finding its Root in University Research
4.7. Development of Multi-Arm Bioprinters: The Next Generation of Bioprinters
5. PROFILES: COMMERCIAL BIOPRTINERS AND PRODUCTS
5.1. Chapter Overview
5.2. Novogen MMX - Organovo
5.2.1. Overview and Origin
5.2.2. Development of NovoGen MMX
5.2.4. Awards and Accomplishments
5.2.5. The Bioprinting Process
5.2.7. Key Features
18.104.22.168. Microtissues for Drug Discovery and Research
22.214.171.124. Longer Term, Organ Printing for Transplantation
126.96.36.199. Regenerative Medicine
5.2.9. Partnerships and Agreements
188.8.131.52. United Therapeutics
184.108.40.206. Methuselah Foundation
5.3. 3D-Bioplotter - EnvisionTEC
5.3.1. Overview and Origin
5.3.2. The Bioprinting Process
220.127.116.11. Provides 'smart' scaffolds for tissue engineering
18.104.22.168. Cell and Tissue Printing
22.214.171.124. 3D-Anatomical Models for Study
5.3.4. Key Features
5.3.5. Academic Institutions using 3D Bioplotter
5.4. BioFactory - regenHU
5.4.1. Overview and Origin
5.4.3. Research Collaborations
126.96.36.199. ETH, Zurich
5.5. BioAssembly Tool - Sciperio / nScrypt
5.5.1. Overview and Origin
5.5.2. The Bioprinting Process
5.5.3. Key Features
188.8.131.52. Cardiovascular Innovation Institute
5.5.5. Awards / Accomplishments
184.108.40.206. Bioficial Heart
220.127.116.11. Other Tissues
5.6. Microfluidic-based Bioprinting Platform - Aspect Biosystems
5.6.1. Overview and Origin
5.6.2. The Bioprinting Process
5.6.3. Key Features
5.6.4. Building Tissue Constructs For Drug Discovery
18.104.22.168. MEMSCAP Design Award 2013
22.214.171.124. Federal Support Through IRAP
5.7. Modified Ink-jet Bioprinter - TeVido BioDevices
5.7.1. Overview and Origin
5.7.3. The Bioprinting Process
5.7.4. Key Features
126.96.36.199. Breast Reconstruction
188.8.131.52. Drug Testing
184.108.40.206. Other Reconstructive Tissue Products
220.127.116.11. Treatment for Chronic Wounds
18.104.22.168. Breast Augmentation
5.8. Other Initiatives
5.8.2. 3DDiscovery - regenHU
22.214.171.124. Key Features
126.96.36.199. Research Collaborations
6. PRODUCT PROFILES: ACADEMIC INSTITUTES
6.1. Chapter Overview
6.2. BioPen - University of Wollongong / St. Vincent Hospital
6.2.1. Overview and Origin
6.2.2. The Bioprinting Process
6.2.3. Advantages of BioPen
6.3. Modified Ink-jet Bioprinter for Skin Cells - Wake Forest Institute for Regenerative Medicine / Armed Forces Institute For Regenerative Medicine
6.3.2. The Bioprinting Process
6.3.3. Key Features
6.3.4. Bioprinting Human Skin
6.3.5. Awards / Accomplishments
6.4. Modified Ink-jet Printer for Tissues and Organs - Wake Forest Institute for Regenerative Medicine
6.4.2. The Bioprinting Process
188.8.131.52. Tissue Patches
184.108.40.206. Potential to Print Organs
220.127.116.11. Organs on a Chip
6.5. Regenovo - Hangzhou Dianzi University, China
6.5.2. The Bioprinting Process
6.5.3. Key Features
6.6. Valve Based Technology - Heriot-Watt University / Roslin Cellab
6.6.1. Overview and Origin
6.6.2. The Bioprinting Process
6.6.3. Key Features
18.104.22.168. Drug Testing for Pharmaceutical Research
22.214.171.124. Tissue Regeneration
126.96.36.199. Custom-built Replacement Organs
6.6.5. Awards / Accomplishments
188.8.131.52. Reinnervate Ltd.
7. MARKET FORECAST
7.1. Chapter Overview
7.2. Forecast Methodology
7.3. The 3D Bioprinting Market, 2014 - 2030
7.3.2. Market Forecast: Drug Testing (Base Scenario)
7.3.3. Market Forecast: 3D Bioprinted Skin (Base Scenario)
7.3.4. Market Forecast: 3D Printed Cartilage Replacement (Base Scenario)
7.3.5. Market Forecast: 3D Printed Organ Transplants (Base Scenario)
7.3.6. Overall Market Forecast (Base Scenario)
8. SWOT ANALYSIS
8.1. Chapter Overview
8.2.1. Faster Drug Discovery
8.2.2. A Quality Alternative to Animal Testing
8.3.1. High Initial Investment
8.3.2. Integration of Vascular Network
8.4.1. Low Entry Barriers
8.4.2. Growing Wait List for Organ Transplants – A Huge Unmet Need
8.5.1. Regulatory Barrier
8.5.2. Commercial 3D Cell Culture Systems
9. CASE STUDIES
9.1. Organovo Holdings, Inc.
10. INTERVIEW TRANSCRIPTS
10.1. Interview 1: n3D Biosciences (Glauco R. Souza, President and CSO & Hubert Tseng, Senior Research Scientist)
10.2. Interview 2: regenHU (Marc Thurner, CEO)
10.3. Interview 3: Sciperio / nScrypt (Kenneth Church, President and CEO & Xudong Chen, Vice President)
10.4. Interview 4: MicroFab Technologies (Anonymous)
10.5. Interview 5: Digilab (Dr. Igor Zlatkin, Application Scientist & Chirantan Kanani, Technology and Product Development)
10.6. Interview 6: TeVido BioDevices (Laura Bosworth, CEO and Co-Founder)
11.1. 3D Bioprinting has Emerged Well Since Inception
11.2. Commercial Bioprinters Are Limited; Research Labs and Spin-outs from Academia Continue to Progress
11.3. Organ Supply - Demand Gap: A Major Growth Driver
11.4. Overall a Multi-billion Dollar Opportunity by 2030
11.5. Challenges Exist Before Bioprinting Becomes Mainstream
12. APPENDIX 1: LIST OF COMPANIES AND ORGANISATIONS
13. APPENDIX 2: TABLES
LIST OF FIGURES
Figure 3.1 The 'Bioprinting' Process
Figure 4.1 Industry Sponsored Bioprinters: Regional Distribution
Figure 4.2 Industry Sponsored Bioprinters: Distribution by Status
Figure 4.3 University Sponsored Bioprinters: Regional Distribution
Figure 5.1 Bioplotter: Printing Process
Figure 7.1 Drug Testing Market, Short-Mid Term, Base Scenario (USD MM)
Figure 7.2 Drug Testing Market, Long Term, Base Scenario (USD MM)
Figure 7.3 3D Bioprinted Skin Market, Short-Mid Term, Base Scenario (USD MM)
Figure 7.4 3D Bioprinted Skin Market, Long Term, Base Scenario (USD MM)
Figure 7.5 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Base Scenario (USD MM)
Figure 7.6 3D Bioprinted Cartilage Replacement Market, Long Term, Base Scenario (USD MM)
Figure 7.7 3D Bioprinted Organ Transplants, Long Term, Base Scenario (USD MM)
Figure 7.8 Overall 3D Bioprinted Products Market, Short-Mid Term, Base Scenario (USD MM)
Figure 7.9 Overall 3D Bioprinted Products Market, Long Term, Base Scenario (USD MM)
Figure 10.1 Process of Magnetic Bioprinting
Figure 10.2 3D Cell Bioprinting: Magnetically Beyond Rings and Dots
Figure 10.3 n3D vs. Organovo 3D Bioprinting
Figure 11.1 3D Bioprinting Market, 2018, 2024, 2030 (USD MM)
Figure 11.2 3D Bioprinting: The Driving Forces
LIST OF TABLES
Table 3.1 RepRap Project: 3D Printing Machines
Table 3.2 Inputs for 3D Bioprinting
Table 4.1 List of Bioprinters: Industry Sponsored
Table 4.2 Companies Developing Bioprinted Products for Commercial Purposes
Table 4.3 Universities Working in the Area of Bioprinting
Table 5.1 NovoGen MMX: Patent Portfolio
Table 5.2 Materials Used for Scaffolds
Table 5.3 SmartPump - Models and Features
Table 7.1: 3D Bioprinted Applications: Launch Timeline
Table 7.2 3D Bioprinted Skin: Competitive Landscape
Table 8.1 SWOT Analysis
Table 8.2 3D Cell Culture Systems
Table 9.1 3D Liver Assays - Launch Timeline
Table 9.2 Organovo's Plans for Revenue Generation from 3D Bioprinted Liver
Table 9.3 Organovo Revenues – 2011, 2012, and Q1 2013
Table 9.4 regenHU: 3D Bioprinting Product Portfolio
Table 13.1 Industry Sponsored Bioprinters: Regional Distribution
Table 13.2 Industry Sponsored Bioprinters: Distribution by Status
Table 13.3 University Sponsored Bioprinters: Regional Distribution
Table 13.4 Drug Testing Market, Short-Mid Term, Base Scenario (USD MM)
Table 13.5 Drug Testing Market, Long Term, Base Scenario (USD MM)
Table 13.6 Drug Testing Market, Short-Mid Term, Conservative Scenario (USD MM)
Table 13.7 Drug Testing Market, Long Term, Conservative Scenario (USD MM)
Table 13.8 Drug Testing Market, Short-Mid Term, Optimistic Scenario (USD MM)
Table 13.9 Drug Testing Market, Long Term, Optimistic Scenario (USD MM)
Table 13.10 3D Bioprinted Skin Market, Short-Mid Term, Base Scenario (USD MM)
Table 13.11 3D Bioprinted Skin Market, Long Term, Base Scenario (USD MM)
Table 13.12 3D Bioprinted Skin Market, Short-Mid Term, Conservative Scenario (USD MM)
Table 13.13 3D Bioprinted Skin Market, Long Term, Conservative Scenario (USD MM)
Table 13.14 3D Bioprinted Skin Market, Short-Mid Term, Optimistic Scenario (USD MM)
Table 13.15 3D Bioprinted Skin Market, Long Term, Optimistic Scenario (USD MM)
Table 13.16 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Base Scenario (USD MM)
Table 13.17 3D Bioprinted Cartilage Replacement Market, Long Term, Base Scenario (USD MM)
Table 13.18 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Conservative Scenario (USD MM)
Table 13.19 3D Bioprinted Cartilage Replacement Market, Long Term, Conservative Scenario (USD MM)
Table 13.20 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Optimistic Scenario (USD MM)
Table 13.21 3D Bioprinted Cartilage Replacement Market, Long Term, Optimistic Scenario (USD MM)
Table 13.22 3D Bioprinted Organ Transplants, Long Term, Base Scenario (USD MM)
Table 13.23 3D Bioprinted Organ Transplants, Long Term, Conservative Scenario (USD MM)
Table 13.24 3D Bioprinted Organ Transplants, Long Term, Optimistic Scenario (USD MM)
Table 13.25 3D Bioprinted Products Market, Short-Mid Term, Base Scenario (USD MM)
Table 13.26 3D Bioprinted Products Market, Long Term, Base Scenario (USD MM)
Table 13.27 3D Bioprinted Products Market, Short-Mid Term, Conservative Scenario (USD MM)
Table 13.28 3D Bioprinted Products Market, Long Term, Conservative Scenario (USD MM)
Table 13.29 3D Bioprinted Products Market, Short-Mid Term, Optimistic Scenario (USD MM)
Table 13.30 3D Bioprinted Products Market, Long Term, Optimistic Scenario (USD MM)
The following companies have been mentioned in the report.
1. 3D Biotek
2. 3D Systems
3. Advanced Biomatrix
5. Aspect Biosystems
8. Avita Medical
9. BD Biosciences
10. Bespoke Innovations
11. Bio3D Technologies
13. CMC Microsystems
15. CP Automation
16. Cuspis LLC
17. Cyfuse Biomedical
23. Hangzhou Dianzi University, China
24. Helisys Inc.
25. Heriot-Watt University
28. InSphero AG
32. Kor Ecologic
34. MakerBot Industries
36. Methuselah Foundation
37. MicroFab Technologies
38. Modern Meadows
39. n3D Biosciences
40. Nano3D Biosciences
41. National Institute of Health
44. Objective 3D
45. Objet Geometries Ltd
46. Organovo Holdings, Inc.
47. Oregon Health & Science University
48. Oxford Performance Materials
51. Rainbow Biosciences
55. Roland DG Corporation
56. Roslin Cellab
58. Sciperio / nScrypt
60. Seattle Genetics
65. TeVido BioDevices
66. The Technology Partnership
67. Unique Technology
68. United Therapeutics
70. Vivos Dental
71. Wake Forest Institute for Regenerative Medicine
75. Z Corporation
77. Zurich University of Applied Sciences
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
Feb. 21, 2017 07:45 AM EST Reads: 312
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
Feb. 21, 2017 07:45 AM EST Reads: 127
It is one thing to build single industrial IoT applications, but what will it take to build the Smart Cities and truly society changing applications of the future? The technology won’t be the problem, it will be the number of parties that need to work together and be aligned in their motivation to succeed. In his Day 2 Keynote at @ThingsExpo, Henrik Kenani Dahlgren, Portfolio Marketing Manager at Ericsson, discussed how to plan to cooperate, partner, and form lasting all-star teams to change the...
Feb. 21, 2017 07:30 AM EST Reads: 4,197
"I think that everyone recognizes that for IoT to really realize its full potential and value that it is about creating ecosystems and marketplaces and that no single vendor is able to support what is required," explained Esmeralda Swartz, VP, Marketing Enterprise and Cloud at Ericsson, in this SYS-CON.tv interview at @ThingsExpo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Feb. 21, 2017 07:15 AM EST Reads: 154
When building large, cloud-based applications that operate at a high scale, it’s important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. “Fly two mistakes high” is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Lee A...
Feb. 21, 2017 07:00 AM EST Reads: 5,247
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Feb. 21, 2017 04:30 AM EST Reads: 1,449
SYS-CON Events announced today that Linux Academy, the foremost online Linux and cloud training platform and community, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Linux Academy was founded on the belief that providing high-quality, in-depth training should be available at an affordable price. Industry leaders in quality training, provided services, and student certification passes, its goal is to c...
Feb. 21, 2017 03:45 AM EST Reads: 900
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at 20th Cloud Expo, Ed Featherston, director/senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Feb. 21, 2017 03:30 AM EST Reads: 3,608
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, discussed how leveraging the Industrial Internet and...
Feb. 21, 2017 03:30 AM EST Reads: 7,589
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
Feb. 21, 2017 03:00 AM EST Reads: 1,632
910Telecom exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and exchanges.
Feb. 21, 2017 02:45 AM EST Reads: 1,378
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, discussed how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a practic...
Feb. 21, 2017 02:00 AM EST Reads: 4,592
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and micro services. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your contain...
Feb. 21, 2017 01:15 AM EST Reads: 3,305
The modern software development landscape consists of best practices and tools that allow teams to deliver software in a near-continuous manner. By adopting a culture of automation, measurement and sharing, the time to ship code has been greatly reduced, allowing for shorter release cycles and quicker feedback from customers and users. Still, with all of these tools and methods, how can teams stay on top of what is taking place across their infrastructure and codebase? Hopping between services a...
Feb. 21, 2017 01:00 AM EST Reads: 6,292
Niagara Networks exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
Feb. 21, 2017 12:30 AM EST Reads: 746